Humanised Mice and Immunodeficient Mice (NSG) Are Equally Sensitive for Prediction of Stem Cell Malignancy in the Teratoma Assay

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 May 14

PMID 35563071

Authors

Monika Bialecka

Joaquin Montilla-Rojo

Bernard A J Roelen

Ad J Gillis

Leendert H J Looijenga

Daniela C F Salvatori

Affiliations

Soon will be listed here.

Abstract

The use of human pluripotent stem cells (hPSCs) in regenerative medicine has great potential. However, it is important to exclude that these cells can undergo malignant transformation, which could lead to the development of malignant tumours. This property of hPSCs is currently being tested using the teratoma assay, through which cells are injected into immunodeficient mice. Transplantation of stem cells in immunocompromised recipient animals certainly has a much higher incidence of tumour formation. On the other hand, the results obtained in immunodeficient mice could indicate a risk of tumour formation that is practically not present in the human immunocompetent recipient. The presence of a humanised immune system might be more representative of the human situation; therefore, we investigated if the demonstrated malignant features of chosen and well-characterised stem cell lines could be retrieved and if new features could arise in a humanised mouse model. Hu-CD34NSG (HIS) mice were compared side by side with immunocompromised mice (NSG) after injection of a set of benign (LU07) and malignant (LU07+dox and 2102Ep) cell lines. Analysis of the tumour development, histological composition, pathology evaluation, and malignancy-associated miRNA expression levels, both in tumour and plasma samples, revealed no differences among mouse groups. This indicates that the HIS mouse model is comparable to, but not more sensitive than, the NSG immunodeficient model for studying the malignancy of stem cells. Since in vivo teratoma assay is cumbersome, in vitro methods for the detection of malignancy are urgently needed.

Citing Articles

Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine.

Wang Z Bioengineering (Basel). 2023; 10(7).

PMID: 37508884 PMC: 10376867. DOI: 10.3390/bioengineering10070857.

Suspension culture improves iPSC expansion and pluripotency phenotype.

Cuesta-Gomez N, Verhoeff K, Dadheech N, Dang T, Jasra I, de Leon M Stem Cell Res Ther. 2023; 14(1):154.

PMID: 37280707 PMC: 10245469. DOI: 10.1186/s13287-023-03382-9.

References

Salvatori D, Dorssers L, Gillis A, Perretta G, van Agthoven T, Gomes Fernandes M . The MicroRNA-371 Family as Plasma Biomarkers for Monitoring Undifferentiated and Potentially Malignant Human Pluripotent Stem Cells in Teratoma Assays. Stem Cell Reports. 2018; 11(6):1493-1505. PMC: 6294243. DOI: 10.1016/j.stemcr.2018.11.002. View

Blum B, Benvenisty N . The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009; 8(23):3822-30. DOI: 10.4161/cc.8.23.10067. View

Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G . Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106(5):1565-73. PMC: 1895228. DOI: 10.1182/blood-2005-02-0516. View

Fleetwood A, Lawrence T, Hamilton J, Cook A . Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol. 2007; 178(8):5245-52. DOI: 10.4049/jimmunol.178.8.5245. View

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro M . Macrophage polarization in tumour progression. Semin Cancer Biol. 2008; 18(5):349-55. DOI: 10.1016/j.semcancer.2008.03.004. View

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

Buta C, David R, Dressel R, Emgard M, Fuchs C, Gross U . Reconsidering pluripotency tests: do we still need teratoma assays?. Stem Cell Res. 2013; 11(1):552-62. PMC: 7615844. DOI: 10.1016/j.scr.2013.03.001. View

Jenkins S, Ruckerl D, Thomas G, Hewitson J, Duncan S, Brombacher F . IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013; 210(11):2477-91. PMC: 3804948. DOI: 10.1084/jem.20121999. View

Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X . Tumor-Associated Macrophages: Recent Insights and Therapies. Front Oncol. 2020; 10:188. PMC: 7052362. DOI: 10.3389/fonc.2020.00188. View

10.

Josephson R, Ording C, Liu Y, Shin S, Lakshmipathy U, Toumadje A . Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells. 2007; 25(2):437-46. DOI: 10.1634/stemcells.2006-0236. View

11.

Gropp M, Shilo V, Vainer G, Gov M, Gil Y, Khaner H . Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny. PLoS One. 2012; 7(9):e45532. PMC: 3458078. DOI: 10.1371/journal.pone.0045532. View

12.

Andrews P, Matin M, Bahrami A, Damjanov I, Gokhale P, Draper J . Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. Biochem Soc Trans. 2005; 33(Pt 6):1526-30. DOI: 10.1042/BST0331526. View

13.

Bouma M, van Iterson M, Janssen B, Mummery C, Salvatori D, Freund C . Differentiation-Defective Human Induced Pluripotent Stem Cells Reveal Strengths and Limitations of the Teratoma Assay and In Vitro Pluripotency Assays. Stem Cell Reports. 2017; 8(5):1340-1353. PMC: 5425621. DOI: 10.1016/j.stemcr.2017.03.009. View

14.

Roa W, Brunet B, Guo L, Amanie J, Fairchild A, Gabos Z . Identification of a new microRNA expression profile as a potential cancer screening tool. Clin Invest Med. 2010; 33(2):E124. DOI: 10.25011/cim.v33i2.12351. View

15.

Andrews P, Ben-David U, Benvenisty N, Coffey P, Eggan K, Knowles B . Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. Stem Cell Reports. 2017; 9(1):1-4. PMC: 7206225. DOI: 10.1016/j.stemcr.2017.05.029. View

16.

Merkle F, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C . Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017; 545(7653):229-233. PMC: 5427175. DOI: 10.1038/nature22312. View

17.

Voorhoeve P, le Sage C, Schrier M, Gillis A, Stoop H, Nagel R . A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124(6):1169-81. DOI: 10.1016/j.cell.2006.02.037. View

18.

van Agthoven T, Eijkenboom W, Looijenga L . microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. Cell Oncol (Dordr). 2017; 40(4):379-388. PMC: 5537315. DOI: 10.1007/s13402-017-0333-9. View

19.

Muller F, Goldmann J, Loser P, Loring J . A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell. 2010; 6(5):412-4. DOI: 10.1016/j.stem.2010.04.009. View

20.

Muller F, Schuldt B, Williams R, Mason D, Altun G, Papapetrou E . A bioinformatic assay for pluripotency in human cells. Nat Methods. 2011; 8(4):315-7. PMC: 3265323. DOI: 10.1038/nmeth.1580. View